SCHEMBL4526286

SCHEMBL4526286

O=c1cc(CO)oc(O)c1O

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.53
POLB P06746 3/20 0.53
ALDH1A1 P00352 3/20 0.53
TDP1 Q9NUW8 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
TYR P14679 1/20 0.50
DAO P14920 1/20 0.50
TEAD4 Q15561 6/20 0.49
MEN1 O00255 1/20 0.47
MAPT P10636 1/20 0.47
KMT2A Q03164 1/20 0.47
GAA P10253 3/20 0.45
TEAD1 P28347 1/20 0.44
TEAD2 Q15562 1/20 0.44
TEAD3 Q99594 1/20 0.44
USP2 O75604 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13078827 0.83 KDM4E (0.53) KDM4EPOLBALDH1A1TDP1L3MBTL1
SCHEMBL3558568 0.81 KDM4E (0.65) KDM4EPOLBALDH1A1TDP1L3MBTL1
SCHEMBL1158367 0.79 KDM4E (0.50) KDM4EPOLBALDH1A1TDP1L3MBTL1
SCHEMBL622814 0.79 KDM4E (0.50) KDM4EPOLBALDH1A1TDP1L3MBTL1
SCHEMBL18120558 0.79 KDM4E (0.66) KDM4EPOLBALDH1A1TDP1L3MBTL1
SCHEMBL11332652 0.79 KDM4E (0.50) KDM4EPOLBALDH1A1TDP1L3MBTL1
SCHEMBL3555239 0.79 KDM4E (0.54) KDM4EPOLBALDH1A1TDP1L3MBTL1
SCHEMBL6786876 0.79 KDM4E (0.50) KDM4EPOLBALDH1A1TDP1L3MBTL1
SCHEMBL13395932 0.76 KDM4E (0.51) KDM4EPOLBALDH1A1TDP1L3MBTL1
SCHEMBL21173510 0.76 KDM4E (0.59) KDM4EPOLBALDH1A1TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152765-A1 Hydroxy-kojic acid skin peel PHYSICIAN'S CHOICE OF ARIZONA, INC. 2004-08-05 US claimed
US-20020082293-A1 Hydroxy-kojic acid skin peel PHYSICIAN'S CHOICE OF ARIZONA, INC. 2002-06-27 US claimed
EP-0422466-A1 Endermic preparation of external application Sansho Seiyaku Co., Ltd. (JP) 1991-04-17 EP claimed
US-7557094-B2 Skin cream composition ETHICS COSMECEUTICALS AB (SE) 2009-07-07 US disclosed
US-7425340-B2 Permeation enhancing compositions for anticholinergic agents ANTARES PHARMA IPL AG (CH) 2008-09-16 US disclosed
EP-1742664-A1 PERMEATION ENHANCING COMPOSITIONS FOR ANTICHOLINERGIC AGENTS Antares Pharma IPL AG (CH) 2007-01-17 EP disclosed
EP-1341517-B1 A SKIN CREAM COMPOSITION ETHICS COSMECEUTICALS AB (SE) 2006-09-06 EP disclosed
US-20050287194-A1 Permeation enhancing compositions for anticholinergic agents ANTARES PHARMA, INC. 2005-12-29 US disclosed
WO-2005107812-A1 PERMEATION ENHANCING COMPOSITIONS FOR ANTICHOLINERGIC AGENTS ANTARES PHARMA IPL AG (CH) 2005-11-17 WO disclosed
US-20040152765-A1 Hydroxy-kojic acid skin peel PHYSICIAN'S CHOICE OF ARIZONA, INC. 2004-08-05 US disclosed
US-20040152765-A1 Hydroxy-kojic acid skin peel PHYSICIAN'S CHOICE OF ARIZONA, INC. 2004-08-05 US disclosed
US-20040043963-A1 Skin cream composition WADLUND AS (NO) 2004-03-04 US disclosed
US-20020082293-A1 Hydroxy-kojic acid skin peel PHYSICIAN'S CHOICE OF ARIZONA, INC. 2002-06-27 US disclosed
US-20020082293-A1 Hydroxy-kojic acid skin peel PHYSICIAN'S CHOICE OF ARIZONA, INC. 2002-06-27 US disclosed
US-6300369-B1 Hydroxy-kojic acid skin peel PHYSICIAN'S CHOICE OF ARIZONA, INC. 2001-10-09 US disclosed
US-6300369-B1 Hydroxy-kojic acid skin peel PHYSICIAN'S CHOICE OF ARIZONA, INC. 2001-10-09 US disclosed
US-5874463-A Hydroxy-kojic acid skin peel PHYSICIAN'S CHOICE OF ARIZONA, INC. 1999-02-23 US disclosed
US-5874463-A Hydroxy-kojic acid skin peel PHYSICIAN'S CHOICE OF ARIZONA, INC. 1999-02-23 US disclosed
EP-0422466-A1 Endermic preparation of external application Sansho Seiyaku Co., Ltd. (JP) 1991-04-17 EP disclosed
EP-0422466-A1 Endermic preparation of external application Sansho Seiyaku Co., Ltd. (JP) 1991-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050287194-A1 Permeation enhancing compositions for anticholinergic agents SLC18A3, SLC14A1, UTS2R KDM4E 4306/4885POLB 610/4885ALDH1A1 3081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.